| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| loxapine | alpha-1a adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | alpha-1b adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | alpha-2a adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | alpha-2b adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | alpha-2c adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | beta-1 adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | muscarinic acetylcholine receptor m1 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | muscarinic acetylcholine receptor m2 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | muscarinic acetylcholine receptor m3 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | muscarinic acetylcholine receptor m4 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | muscarinic acetylcholine receptor m5 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | d(1) dopamine receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.13 | approved | binder |
| loxapine | dopamine d1 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.13 | approved | antagonist |
| loxapine | dopamine d2 receptor | small molecule | Successful target | TTD , drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.48 | approved | antagonist |
| loxapine | dopamine d3 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.16 | approved | binder,antagonist |
| loxapine | dopamine d4 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.22 | approved | binder,antagonist |
| loxapine | dopamine d5 receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | d(1) dopamine receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | histamine h1 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.05 | approved | binder,antagonist |
| loxapine | histamine h2 receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | histamine h4 receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 1b | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 1d | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 1e | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.19 | approved | antagonist |
| loxapine | 5-hydroxytryptamine receptor 2c | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.22 | approved | antagonist |
| loxapine | 5-hydroxytryptamine receptor 3a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 5a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | 5-hydroxytryptamine receptor 6 | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.16 | approved | binder,antagonist |
| loxapine | 5-hydroxytryptamine receptor 7 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | sodium-dependent noradrenaline transporter | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | sodium-dependent dopamine transporter | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| loxapine | sodium-dependent serotonin transporter | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Schizophrenia[MeSHID:D012559] Psychotic Disorders[MeSHID:D011618] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | binder |
| click here to return to the previous page | ||||||||